Related Experiment Videos
[Early serological diagnosis of nephropathia epidemica]
D Wiger1, I E Børsting, R Mehl
1Avdeling for Virologi, Statens Institutt for Folkehelse, Oslo.
Abstract:
The viral disease nephropathia epidemica is probably more common throughout Norway than previously reported. Since 1986, outbreaks of the disease have been registered every year but in different regions of the country. Very few cases have been reported in certain counties in spite of the presence of a small rodent reservoir for this zoonosis. Nephropathia epidemica may be underdiagnosed, since the disease is not equally well recognized in all parts of Norway. However, effective and reliable serological diagnostic tests are now available which use a single serum sample taken early in the acute phase of the disease. Test results are available at a time when they can help the physician to make an early diagnosis. This should lead to a more effective and rational treatment of these patients.
Insights
Nephropathia epidemica, a viral disease, is likely underdiagnosed in Norway. New serological tests enable earlier diagnosis and more effective treatment of this zoonosis.
Area of Science:
- Epidemiology
- Infectious Diseases
- Viral Hemorrhagic Fevers
Context:
- Nephropathia epidemica (NE) outbreaks occur annually in Norway but vary regionally.
- Underdiagnosis of NE is suspected due to inconsistent recognition across different Norwegian counties.
- The presence of a rodent reservoir suggests NE is a potential public health concern.
Purpose:
- To highlight the probable underdiagnosis of NE in Norway.
- To emphasize the availability of new, effective serological diagnostic tests for NE.
- To advocate for earlier diagnosis and improved patient management.
Summary:
- Despite annual outbreaks since 1986, Nephropathia epidemica (NE) may be underdiagnosed in Norway.
- Effective serological tests are now available for early-phase diagnosis using a single serum sample.
- These advancements facilitate timely diagnosis, potentially leading to more rational and effective patient treatment.
Impact:
- Increased awareness and diagnosis of NE in Norway.
- Improved patient outcomes through earlier and more targeted treatment strategies.
- Better understanding of NE epidemiology and public health implications within Norway.